Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Janssen Completes Divestiture | Contract Pharma

What are you searching for?

Sign in
Breaking News

Janssen Completes Divestiture

U.S. license rights to Nucynta family of products sold to Depomed

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Janssen Pharmaceuticals, Inc. has completed the divestiture of its U.S. license rights to Nucynta (tapentadol), Nucynta ER extended-release tablets and Nucynta oral solution to Depomed for $1.05 billion.

Janssen’s licensed U.S. commercialization rights to Nucynta products from Grunenthal GmbH were assigned to Depomed. Janssen will retain license rights to the products in Canada, Japan, and a number of other countries outside the U.S.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters